The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Akash Sethi
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 0.6 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Akash Sethi, Promoter and Joint Managing Director of Shree Pacetronix Ltd, acquired 1,78,000 equity shares on June 8, 2026 through an off-market transfer from Bio Pace Technology INC (a fellow promoter-group entity). His stake in the company increased from 4,78,771 shares (8.76%) to 6,56,771 shares (13.51%) post the transaction — a rise of about 4.75 percentage points. On a diluted basis (including conversion of warrants into equity), his holding moves from 12.28% to 16.84%. This is essentially a reshuffling of shares within the promoter group, not new money coming in or going out of the company.
This is an internal promoter-group share reshuffle rather than a meaningful change in overall promoter ownership strength, so the impact on the stock is expected to be neutral. Akash Sethi's individual influence over the company has however clearly risen, taking him from a junior to a more substantial promoter stake-holder.